{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T05:07:13Z","timestamp":1779512833758,"version":"3.53.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.coi.2026.102782","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:10:28Z","timestamp":1777590628000},"page":"102782","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Outcome measures in systemic lupus erythematosus"],"prefix":"10.1016","volume":"100","author":[{"given":"Sumatha Channapatna","family":"Suresh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Furie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2998-1055","authenticated-orcid":false,"given":"Sonali","family":"Narain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2026.102782_bib1","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard-2022-223035","article-title":"Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study","volume":"82","author":"Tian","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102782_bib2","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/art.1780350606","article-title":"Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE","volume":"35","author":"Bombardier","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2026.102782_bib3","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.coi.2026.102782_bib4","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1191\/096120399680411281","article-title":"Classification and definition of major flares in SLE clinical trials","volume":"8","author":"Petri","year":"1999","journal-title":"Lupus"},{"key":"10.1016\/j.coi.2026.102782_bib5","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa051135","article-title":"Combined oral contraceptives in women with systemic lupus erythematosus","volume":"353","author":"Petri","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2026.102782_bib6","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2026.102782_bib7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2026.102782_bib8","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/rheumatology\/keh624","article-title":"BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus","volume":"44","author":"Isenberg","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102782_bib9","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1093\/rheumatology\/keab883","article-title":"Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004 index","volume":"61","author":"Carter","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102782_bib10","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1191\/096120300678828640","article-title":"The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus","volume":"9","author":"Mosca","year":"2000","journal-title":"Lupus"},{"key":"10.1016\/j.coi.2026.102782_bib11","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/art.1780310701","article-title":"Measurement of systemic lupus erythematosus activity in clinical research","volume":"31","author":"Liang","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2026.102782_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2014-000075","article-title":"Preliminary test of the LFA rapid evaluation of activity in lupus (LFA-REAL): an efficient outcome measure correlates with validated instruments","volume":"2","author":"Askanase","year":"2015","journal-title":"Lupus Sci Med"},{"issue":"Supplement 1","key":"10.1016\/j.coi.2026.102782_bib13","first-page":"2650","article-title":"LFA-REAL outperforms SLEDAI and BILAG in detecting clinical change in lupus activity","volume":"77","author":"Nordmann-Gomes","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2026.102782_bib14","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/annrheumdis-2018-214502","article-title":"Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity","volume":"78","author":"Jesus","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102782_sbref15","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.1093\/rheumatology\/keaf366","article-title":"Validation of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) in Brazilian SLE patients","volume":"64","author":"Mata-Machado","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102782_bib16","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/annrheumdis-2021-220363","article-title":"Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity","volume":"80","author":"Jesus","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102782_sbref17","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2025-001499","article-title":"SLE-DAS enables an accurate definition of severe lupus disease activity: derivation and validation in a post hoc study of anifrolumab phase II and III studies","volume":"12","author":"Jesus","year":"2025","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.coi.2026.102782_bib18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/annrheumdis-2022-eular.2769","article-title":"OP0147\u2005the SLE-DAS remission and low disease activity states discriminate drug from placebo and better health-related quality of life: post-hoc analysis of the BLISS-52 and BLISS-76 phase III trials","volume":"81","author":"Jesus","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102782_bib19","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/art.24698","article-title":"Novel evidence-based systemic lupus erythematosus responder index","volume":"61","author":"Furie","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2026.102782_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2013-000005","article-title":"Which outcome measures in SLE clinical trials best reflect medical judgment?","volume":"1","author":"Thanou","year":"2014","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.coi.2026.102782_bib21","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/annrheumdis-2021-221847","article-title":"Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2\/3 trials","volume":"81","author":"Bruce","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102782_sbref22","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2024-001484","article-title":"Domains for inclusion in a novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): results of a modified Delphi study","volume":"12","author":"Connelly","year":"2025","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.coi.2026.102782_bib23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/art.1780390303","article-title":"The development and initial validation of the Systemic Lupus International Collaborating Clinics\/American College of Rheumatology damage index for systemic lupus erythematosus","volume":"39","author":"Gladman","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2026.102782_sbref24","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2024-001206","article-title":"Patients achieving low lupus disease activity state, systemic lupus erythematosus disease control or remission showed lower rates of organ damage during longitudinal follow-up: analysis of the Hopkins Lupus Cohort","volume":"11","author":"Hunnicutt","year":"2024","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.coi.2026.102782_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2020-000412","article-title":"Comparative analysis of long-term organ damage in patients with systemic lupus erythematosus using belimumab versus standard therapy: a post hoc longitudinal study","volume":"7","author":"Urowitz","year":"2020","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.coi.2026.102782_sbref26","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.ard.2025.01.025","article-title":"Reduced organ damage accumulation in adult patients with SLE on anifrolumab plus standard of care compared to real-world external controls","volume":"84","author":"Touma","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102782_bib27","article-title":"33 Revised SDI","volume":"11","author":"Bruce","year":"2024","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.coi.2026.102782_bib28","first-page":"44","article-title":"The value of repeat kidney biopsy in lupus nephritis. A systematic review","volume":"28","author":"S\u00e1nchez-Cub\u00edas","year":"2021","journal-title":"Rev Colomb Reumatol"},{"key":"10.1016\/j.coi.2026.102782_sbref29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103165","article-title":"Proximity extension assay proteomics and renal single cell transcriptomics uncover novel urinary biomarkers for active lupus nephritis","volume":"143","author":"Li","year":"2024","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2026.102782_sbref30","article-title":"03 Update on urinary biomarkers in lupus nephritis","volume":"12","author":"Fava","year":"2025","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.coi.2026.102782_bib31","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1001\/archdermatol.2010.435","article-title":"Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus","volume":"147","author":"Klein","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.coi.2026.102782_bib32","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1136\/annrheumdis-2022-eular.5149","article-title":"AB0571\u2005derivation and independent validation of the Lupus Arthritis and Musculoskeletal Disease Activity score (LAMDA): a more sensitive, specific and responsive tool for lupus arthritis","volume":"81","author":"Mahmoud","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102782_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103773","article-title":"Framework for implementing treat-to-target in systemic lupus erythematosus routine clinical care: consensus statements from an international task force","volume":"24","author":"Piga","year":"2025","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.coi.2026.102782_sbref34","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/S2665-9913(24)00121-8","article-title":"Association of sustained Lupus Low Disease Activity State with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study","volume":"6","author":"Golder","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.coi.2026.102782_bib35","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/rheumatology\/kew377","article-title":"Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus","volume":"56","author":"Tsang-A-Sjoe","year":"2016","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102782_bib36","doi-asserted-by":"crossref","first-page":"e822","DOI":"10.1016\/S2665-9913(22)00304-6","article-title":"Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study","volume":"4","author":"Kandane-Rathnayake","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.coi.2026.102782_bib37","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/acr.24063","article-title":"Time to lupus low disease activity state in the Hopkins Lupus Cohort: role of African American Ethnicity","volume":"72","author":"Babao\u011flu","year":"2020","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.coi.2026.102782_sbref38","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/ard-2023-224919","volume":"83","author":"Pitsigavdaki","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102782_bib39","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/annrheumdis-2018-214427","article-title":"Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus","volume":"78","author":"Oon","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102782_bib40","doi-asserted-by":"crossref","first-page":"e751","DOI":"10.1016\/S2665-9913(24)00162-0","article-title":"Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials","volume":"6","author":"Parodis","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.coi.2026.102782_bib41","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3899\/jrheum.2025-0390.PV269","article-title":"Lupus Low Disease Activity State attainment and reduced glucocorticoid use in patients with systemic lupus erythematosus in the tulip long-term extension trial of anifrolumab","volume":"52","author":"Morand","year":"2025","journal-title":"J Rheumatol"},{"key":"10.1016\/j.coi.2026.102782_sbref42","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/rheumatology\/keae120","article-title":"Lupus Low Disease Activity State and organ damage in relation to quality of life in systemic lupus erythematosus: a cohort study with up to 11 years of follow-up","volume":"64","author":"Parodis","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102782_bib43","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.coi.2026.102782_bib44","first-page":"97","article-title":"Updating the OMERACT Systemic Lupus Erythematosus Core Outcome Set","volume":"52","author":"Nielsen","year":"2025","journal-title":"J Rheumatol"},{"key":"10.1016\/j.coi.2026.102782_bib45","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1016\/S2665-9913(25)00022-0","article-title":"Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trial","volume":"7","author":"Strand","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.coi.2026.102782_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/PROM.S369584","article-title":"Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: insights from clinical trials and real-world evidence","volume":"14","author":"Gomez","year":"2023","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1016\/j.coi.2026.102782_sbref47","article-title":"P134 Factors associated with discordance between patient and physician perception of disease activity among patients with systemic lupus erythematosus: an international collaborative study","volume":"11","author":"Ghosh","year":"2024","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.coi.2026.102782_sbref48","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1093\/rheumatology\/keae341","article-title":"Predictive validity of Lupus Patient-Reported Outcome for damage accrual in patients with systemic lupus erythematosus: the LUNA Registry","volume":"64","author":"Nose","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102782_bib49","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1002\/acr.25143","article-title":"Development of American College of Rheumatology Quality Measures for Systemic Lupus Erythematosus: a modified Delphi process with Rheumatology Informatics System for Effectiveness (RISE) Registry data review","volume":"75","author":"Bartels","year":"2023","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.coi.2026.102782_bib50","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s41687-024-00832-7","article-title":"Identifying meaningful aspects of health and concepts of interest for assessment in systemic lupus erythematosus: implications for digital clinical measure development","volume":"8","author":"Kamudoni","year":"2024","journal-title":"J Patient Rep Outcomes"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791526000592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791526000592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T04:24:22Z","timestamp":1779510262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791526000592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":50,"alternative-id":["S0952791526000592"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2026.102782","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcome measures in systemic lupus erythematosus","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2026.102782","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102782"}}